Cyclosporin A (CsA) was introduced in recent years for the treatment of lupus nephritis in patients with steroid resistance or in those with severe corticosteroid toxicity. Our previous study on paediatric patients showed that Neoral (a new microemulsion formulation) had better bioavailability than CsA capsules. To evaluate the clinical efficacy of Neoral in children with lupus nephritis compared with conventional therapy, we performed an open randomized study on 40 children, ranging from 9 to 14 yr old, with class III-V lupus nephritis and heavy proteinuria. They were randomly assigned to either Neoral (5 mg/kg/day), administered q.12.h, or prednisolone (2 mg/kg/day) plus cyclophosphamide (2 mg/kg/day) for 1 yr. Both groups showed a significant decrease in proteinuria (Neoral: 4.62 ± 1.93 to 0.35 ± 0.29 g/day, P < 0.05; prednisolone plus cyclophosphamide: 4.52 ± 1.86 to 0.62 ± 0.21 g/day, P < 0.01). The CH 50 haemolytic assay titre decreased after 1 yr of Neoral treatment (26.5 ± 0.9 to 21.4 ± 2.2 U/ml, P < 0.05). Serum C3 and anti-double-stranded (ds) DNA antibody levels also fell with Neoral (C3: 86.2 ± 6.8 to 76.3 ± 4.5 mg/dl; anti-ds DNA antibodies: 14.1 ± 3.2 to 8.2 ± 1.4 IU/ml, P < 0.05). The Neoral group had a significant increase in growth rate over the prednisolone plus cyclophosphamide group (8.2 ± 1.1 cm/yr vs 2.7 ± 0.6 cm/yr, P < 0.01) with improvement of growth status. During the study period, patients tolerated Neoral well with no significant changes in renal function, liver function or lipid profile. Our study implies that Neoral appears to be effective in suppressing proteinuria. Neoral should be regarded as being adjunctive therapy, perhaps with a steroid-sparing effect, in paediatric lupus nephritis. However, its long-term use awaits further studies.
T prognosis of systemic lupus erythematosus (SLE) lations. The actual amount absorbed by patients can vary from <5% to >90% [9, 10] . with lupus nephritis has improved in recent decades [1] . Before 1970, <40% of patients survived for 5 yr CsA Neoral, a new microemulsion formulation of CsA, has a markedly less variable pharmacokinetic [2] , while the 10 yr patient and kidney survival rates are now around 90% in some series [1, 3] . Our group profile, enabling systemic exposure to be predicted more precisely [11] . There is an improved dose linearity showed that the 5 yr renal and patient survival rates of children with class IV diffuse proliferative glomin CsA exposure (AUC ), a more consistent absorption profile, and Neoral is less influenced by concomitant erulonephritis were 87.7 and 82%, respectively [4] . This favourable outcome might be explained by more food intake and diurnal rhythm [12] . These properties combine to give less intra-and interpatient variability. accurate diagnosis with renal biopsy and more aggressive treatment with immunosuppressive agents. HowUp to now, no study of Neoral had been performed in paediatric lupus nephritis. Therefore, we conducted ever, the major advance in the treatment of SLE was obtained at the price of side-effects and toxicity of an open randomized trial to evaluate the clinical efficacy of Neoral in paediatric lupus nephritis with heavy corticosteroids and cytotoxic drugs, such as myelosuppression, gastrointestinal bleeding, haemorrhagic proteinuria. cystitis and osteoporosis. In paediatric patients, growth METHODS retardation is also a serious complication.
In recent years, cyclosporin A (CsA) has been From July 1994 to December 1995, 40 children with heavy proteinuria, aged from 10 to 14 yr old, with reported as an effective and safer alternative in the treatment of SLE [5] . The main concern about the class III-V lupus nephritis and normal creatinine clearance (CCr) were selected. They fulfilled four or use of CsA in lupus nephritis is its nephrotoxicity [6 ] . The nephrotoxicity is related to the serum trough more of the 1982 Revised American Rheumatism Association criteria for SLE [13] . Lupus nephritis was level or area under the curve (AUC ) of CsA [7] . Unfortunately, the absorption of oral CsA varies proven by renal biopsy after parental consent during onset of disease. The kidney biopsy specimens were widely, both within patients and between patients [8] . Oral bioavailability averages~30% [9] , with equal divided into three parts for light, immunofluorescence and electron microscope studies as described previbioavailability for the CsA solution and capsule formuously [4] . Before entering this study, all the patients had The CH 50 haemolytic assay was carried out using the therapy were continued until control of lupus activity standard method [4, 14] . Timed urine collections for with immunological improvement (elevation of serum the determination of CCr were made for 24 h from 7 C3, C4 level and CH 50 haemolytic titre, decrease in a.m. to 7 a.m. the next day. The CCr was corrected to anti-double-stranded (ds) DNA antibody level, etc.).
a body surface area of 1.73 m2. Hypertension was We then tapered the dose of prednisolone between 0.5 defined as both systolic and diastolic blood pressure and 1 mg/kg/day as maintenance therapy for >1 yr.
>95th percentile for the respective age groups. Height All of them had persistent heavy proteinuria with 24 h was measured with a Harpenden stadiometer, always urine protein of >2 g/day and were unable to decrease at the same time of the day, and the measurement was the dosage of prednisolone further. With the above repeated until three consecutive readings agreed within regimen, all the patients received oral prednisolone a range of 0.2 cm. Baseline mean height was expressed with or without pulse therapy for 1-3 yr. They also as standard deviation score (SDS) (= height − expechad growth retardation below −1.5 standard deviation ted height at that age/.. for expected height at that score (SDS) during prednisolone treatment. Mineral age) [15] . All the above data were recorded each supplements including calcium carbonate were premonth. scribed to each patient. Their serum calcium, phosphorus, alkaline phosphatase and intact parathyroid Statistical analysis hormone levels were within normal ranges. Their bone
The statistical significance of differences between age also corresponded to their chronological age. No groups was evaluated using Student's t-test. The level patient had evidence of delayed puberty.
of significance was set at a = 0.05. Values are expressed All the patients were randomly assigned to either as the mean ± .. CsA Neoral or prednisolone plus cyclophosphamide therapy. The indication for therapy was contained in RESULTS sealed, completely opaque, envelopes numbered in Forty children with class III-V lupus nephritis with sequence according to a table of random numbers.
heavy proteinuria were randomized into two groups. The enrolment of new patients ended in March 1995,
The baseline characteristics of both groups are sumwhen the planned number of 20 patients in each group marized in Table I . There was no significant difference was reached. This was considered sufficient to have a for any item between the two groups. The CCr and power of 0.80 for demonstrating a 0.05 increase in the liver function were within the normal range in both cumulative proportion of clinical response in the congroups. All had nephrotic-range proteinuria. None had trol group vs a 0.40 increase in the Neoral group at hypertension. The magnitude of proteinuria decreased month 12, using a two-tailed statistical test performed significantly after 1 yr of treatment in both groups at the 0.05 significance level. In group 1, the patients (Neoral: 4.62 ± 1.93 to 0.35 ± 0.29 g/day, P < 0.05; were started with CsA Neoral 5 mg/kg/day, adminisprednisolone plus cyclophosphamide: 4.54 ± 1.86 to tered q.12.h; then the doses were adjusted to maintain the trough levels between 75 and 150 ng/ml, as meas- cium channel blockers, were given to any patient who developed hypertension during the study period.
All not significant.
The clinical and serological features were recorded
Cr, creatinine; CCr, creatinine clearance. Data are expressed as the mean ± ..
during each visit. Serum anti-ds DNA antibody, CH 50 There was no difference in liver function, cholesterol or triglyceride levels after 1 yr of treatment in both groups. *Two patients were dropped from the Neoral group due to acute exacerbation which needed methylprednisolone pulse therapy.
0.62 ± 0.21 g/day, P < 0.01). No significant decline in litus, paraesthesia and tremor, were not observed during treatment. CCr was noted with Neoral. The CH 50 haemolytic titre decreased after 1 yr of Neoral treatment DISCUSSION (26.5 ± 0.9 U/ml to 21.4 ± 2.2 U/ml, P < 0.05) (CH 50 normal range: 27.8 ± 0.3 U/ml ). A decrease in C3 level
In the present study, we proved that Neoral is as effective as conventional therapy in decreasing prowas noted in the Neoral group. Both groups showed a significant decrease in anti-ds DNA antibody titre teinuria in paediatric lupus nephritis with heavy proteinuria. Moreover, no decrease in glomerular filtration ( Table II ) . In our study, two patients in the Neoral group were withdrawn from the assignment due to rate (GFR) was noted with Neoral during the study period. However, we did note some patients who acute exacerbation which needed vigorous therapy.
A significant improvement in growth velocity was showed a decline of GFR during Neoral treatment. Fortunately, normalization of GFR was noted after noted in the Neoral group. All patients had a growth curve below −1.5 SDS before entry into the study.
tapering the dose of CsA. It is well known that CsA may induce functional change even when the theraSubstitution of Neoral instead of corticosteroids showed recovery of growth velocity, from 2.7 ± 0.6 to peutic dose range is prescribed. We did not perform repeated renal biopsies to evaluate the possible renal 8.2 ± 1.1 cm/year, and catch-up growth height, from −1.6 ± 0.5 to −0.8 ± 0.2 SDS, in group 1 patients toxicity of Neoral. However, others have observed long-term renal lesions on repeated biopsies in children ( Table III ) . However, there was no change in growth pattern in group 2 patients. following a long course of CsA therapy, even when the initial biopsies were considered normal [16 ] . If a The CsA-related side-effects were mild. There were no differences in liver function, cholesterol or triglycermore prolonged course is given (>1 yr), renal biopsy is warranted to detect deleterious nephrotoxicity even ide levels after 1 yr of treatment in both groups. Renal function and CCr showed no significant change after when the CCr is normal, especially in lupus nephritis. The mode of action of CsA in reducing proteinuria Neoral treatment, and the values between the two groups did not differ at any time. Four Neoral-treated is yet to be fully elucidated. It has been postulated that CsA may interfere with lymphokine production patients complained of gingival hyperplasia. The incidence of hirsutism was greater in the Neoral group. [17] . An alternative, non-immunological mechanism is by alteration of intrarenal haemodynamics, because Other side-effects, such as hypertension, diabetes mel- Height velocity (cm/year) 2.7 ± 0.6* 8.2 ± 1.1* † 2.8 ± 0.7 2.7 ± 0.6 † Height SDS −1.6 ± 0.5* −0.8 ± 0.2* † −1.7 ± 0.6 −1.8 ± 0.5 † Height SDS, height standard deviation score. Data are expressed as the mean±.. All patients suffered from growth retardation below −1.5 SDS before entry into the study. Growth velocity increased significantly after 1 yr with Neoral, but remained unchanged in the prednisolone+cyclophosphamide group. *, †P<0.01.
CsA is recognized to cause intrarenal vasoconstriction, In conclusion, Neoral appears to be effective in decreasing proteinuria in paediatric patients with lupus probably of the afferent arterioles, associated with a decrease in GFR [18] . More recent work has suggested nephritis. However, its effect in controlling disease activity remains controversial. Neoral should be that CsA restores charge selectivity to the glomerular basement membrane, thereby reducing the membrane envisaged as being adjunctive therapy with steroidsparing benefits in proliferative and membranous lupus permeability [19] .
Our data imply a significant decrease in CH 50 haenephritis. However, widespread and long-term use of this potentially nephrotoxic drug in the management molytic titre in the Neoral group, which was not observed in the prednisolone plus cyclophosphamide of patients with SLE and various forms of lupus nephritis need further controlled trials. group. Moreover, the serum C3 level decreased with Neoral treatment. However, the level of anti-ds DNA decreased in both groups. It seems that Neoral alone A is not effective in controlling serological activity. These
The authors thank Shiu-Chih Tsay for the measureresults are similar to those reported by Feutren et al. ment of serum CH 50 haemolytic titres. [20] . In 13 steroid-resistant/dependent patients treated with CsA, their mean proteinuria decreased, and lupus R serologies (ANA, anti-ds DNA, complement) were
